BUFFALO, NY--(Marketwire - September 30, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today
announced that the Joint Science and Technology Office for Chemical and
Biological Defense at the Defense Threat Reduction Agency of the Department
of Defense awarded the Armed Forces Radiobiology Research Institute (AFRRI)
a $612,000 grant to study, with technical assistance from the Company,
select compounds within Cleveland BioLabs's Protectan 600 series for
development as a radiation countermeasure for treatment of acute radiation
syndrome.
Michael Fonstein, Ph.D., Chief Executive Officer and President of Cleveland
BioLabs, stated, "We have enjoyed successful collaborative relationships
with both the Department of Defense and AFRRI and look forward to extending
our collective efforts to further research on our 600 series of Protectan
compounds."
Cleveland BioLabs's Protectan 600 series of compounds are proprietary
synthetic agents that have demonstrated radioprotective and radiomitigating
effects in animal studies. Research into the mechanism of action behind
these effects has determined that the 600 series of compounds are powerful
inducers of hematopoietic stem cells in bone marrow and mobilizers of these
stem cells into peripheral blood.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries around programmed cell death to
develop treatments for cancer and protection of normal tissues from
exposure to radiation and other stresses. The Company has strategic
partnerships with the Cleveland Clinic, Roswell Park Cancer Institute,
ChemBridge Corporation and the Armed Forces Radiobiology Research
Institute. To learn more about Cleveland BioLabs, Inc., please visit the
company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Some of
the factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in the Company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission on March 30, 2009.
